DK1237584T3 - Receptorbindende konjugater - Google Patents

Receptorbindende konjugater

Info

Publication number
DK1237584T3
DK1237584T3 DK00980133.3T DK00980133T DK1237584T3 DK 1237584 T3 DK1237584 T3 DK 1237584T3 DK 00980133 T DK00980133 T DK 00980133T DK 1237584 T3 DK1237584 T3 DK 1237584T3
Authority
DK
Denmark
Prior art keywords
receptor binding
present
conjugate
binding conjugates
prepare
Prior art date
Application number
DK00980133.3T
Other languages
English (en)
Inventor
Gjermund Henriksen
Roy H Larsen
Original Assignee
Anticancer Therapeutic Inv S As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Therapeutic Inv S As filed Critical Anticancer Therapeutic Inv S As
Application granted granted Critical
Publication of DK1237584T3 publication Critical patent/DK1237584T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK00980133.3T 1999-12-06 2000-12-05 Receptorbindende konjugater DK1237584T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO19995978A NO314537B1 (no) 1999-12-06 1999-12-06 Reseptorbindende konjugater
PCT/NO2000/000413 WO2001039806A1 (en) 1999-12-06 2000-12-05 Receptor binding conjugates

Publications (1)

Publication Number Publication Date
DK1237584T3 true DK1237584T3 (da) 2011-07-18

Family

ID=19904060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00980133.3T DK1237584T3 (da) 1999-12-06 2000-12-05 Receptorbindende konjugater

Country Status (11)

Country Link
US (3) US6740304B2 (da)
EP (1) EP1237584B1 (da)
JP (1) JP5153044B2 (da)
AT (1) ATE505208T1 (da)
AU (1) AU1743201A (da)
DE (1) DE60045847D1 (da)
DK (1) DK1237584T3 (da)
ES (1) ES2364811T3 (da)
NO (1) NO314537B1 (da)
PT (1) PT1237584E (da)
WO (1) WO2001039806A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
JP4868698B2 (ja) * 2001-05-02 2012-02-01 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
GR1004274B (el) * 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
EA200500210A1 (ru) 2002-07-16 2005-06-30 Медексис С. А. Конъюгаты стероидов, их получение и их применение
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
NZ543044A (en) * 2003-04-15 2010-04-30 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
ATE412897T1 (de) 2003-05-30 2008-11-15 Purdue Research Foundation Diagnoseverfahren für atherosklerose
EA020542B1 (ru) * 2004-02-20 2014-12-30 Алгета Ас Альфа-излучающие частицы гидроксиапатита
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
CN101128152A (zh) * 2004-12-23 2008-02-20 普渡研究基金会 发射正电子段层成像方法
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
CA2685300C (en) 2006-06-01 2017-01-03 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
EP2109466B1 (en) 2007-02-07 2014-11-12 Purdue Research Foundation Positron emission tomography imaging method
WO2008148001A2 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
CN101985471B (zh) * 2009-07-29 2014-04-30 上海汉升生物科技有限公司 叶酸-IgG偶联物及其制备方法与应用
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
ES2843625T3 (es) 2014-06-18 2021-07-19 Alpha Therapy Solutions Ab Plataforma de proceso automático para la producción de radiofármacos marcados con astatina-211 [At-211]
CN121219012A (zh) * 2023-06-04 2025-12-26 阿拉里斯生物技术股份公司 用于治疗癌症的双有效载荷抗体药物缀合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336185A (en) 1976-03-02 1982-06-22 Rohm And Haas Company Folic acid derivatives
DE3436177A1 (de) * 1984-10-03 1986-04-03 Goldschmidt Ag Th Verwendung von polyoxyalkylen-polysiloxan-copolymerisaten mit an siliciumatomen gebundenen langkettigen alkylresten als emulgatoren zur herstellung von w/o-emulsionen
EP0282057A3 (en) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5547668A (en) 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
WO1997041898A1 (en) * 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
ATE505208T1 (de) 2011-04-15
NO314537B1 (no) 2003-04-07
PT1237584E (pt) 2011-05-02
DE60045847D1 (de) 2011-05-26
EP1237584B1 (en) 2011-04-13
US6740304B2 (en) 2004-05-25
US20150258223A1 (en) 2015-09-17
JP5153044B2 (ja) 2013-02-27
JP2003515570A (ja) 2003-05-07
ES2364811T3 (es) 2011-09-14
AU1743201A (en) 2001-06-12
NO995978D0 (no) 1999-12-06
EP1237584A1 (en) 2002-09-11
NO995978L (no) 2001-06-07
US20040184990A1 (en) 2004-09-23
US20010008625A1 (en) 2001-07-19
WO2001039806A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
DE60045847D1 (de) Rezeptorbindende konjugate
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
MXPA03004832A (es) Compuestos y sus usos.
WO2003059251A3 (en) Antibody targeting compounds
DE60042369D1 (de) Chemisch programmierbare immunität
NO20021701L (no) Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel
GT200000103A (es) Trifluorbutenos nematocidas.
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
TR200102401T2 (tr) C-21 Değiştirilmiş epotilonlar.
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
AU2002215904A1 (en) Compounds with a branched linker
SE9901077D0 (sv) Novel use
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
GB9921592D0 (en) Preparation of highly pure toxin fragments
NO985462D0 (no) Karbohydrat-derivater og fastfase-syntese derav
TR200102741T2 (tr) Resorsinol bileşimi
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
WO2001040239A3 (en) Transition metal-cyclopentadienyl-tropane conjugates
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
WO2002017920A3 (en) Use of methylphenidate compounds to enhance memory
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.